Patients with moderate-to-severe atopic dermatitis (AD) experienced sustained improvements in skin signs/symptoms through 140 weeks while receiving upadacitinib and rates of long-term patient-related outcome improvements were numerically higher with upadacitinib 30 mg compared with upadacitinib 15 mg, according to a study presented at the Revolutionizing Atopic Dermatitis (RAD) Conference this month in Chicago, Illinois.
In “Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies,” Vimal H. Prajapati, MD, and colleagues explained that they sought to evaluate the effects of upadacitinib monotherapy on skin and patient-reported outcomes in patients with moderate-to-severe AD over 140 weeks.
At week 16, more than 50% of patients receiving either 15 mg or 30 mg of upadacitinib reported clinically meaningful improvements in patient-related outcomes; 36.7% and 53.1% achieved worst pruritis numerical rating scale (WP-NRS) 0/1, while 29.0% and 44.1% achieved dermatology quality of life index (DLQI) 0/1, and 23.5% and 50.0% achieved children’s dermatology quality of life (CDLQI) 0/1, respectively. Response rates at week 16 were sustained or improved further through week 140. At week 140, the proportion of patients treated with upadacitinib 15 mg and upadacitinib 30 mg from baseline who achieved clinically meaningful improvements were 64.8% and 70.9% for itch, 74.6% and 81.5% for skin pain, 67.6% and 75.4% for skin symptoms, 89.0% and 94.2% for skin symptom severity, 76.5% and 84.0% for sleep, 79.2% and 84.0% for daily activities, and 78.6% and 82.7% for emotional state, respectively. At week 140, achievement rates with upadacitinib 15 mg and upadacitinib 30 mg were 45.1% and 51.4% for WP-NRS 0/1, 67.3% and 75.6% for eczema area and severity index (EASI) 90, 40.5% and 47.1% for simultaneous EASI 90 and WP-NRS 0/1 achievement, 40.2% and 48.5% for DLQI 0/1, and 35.7% and 65.0% for CDLQI 0/1, respectively.